Skip to main content
SpringerLink
Log in

Idiopathic Inflammatory Myopathies

  • Chapter
Primer on the Rheumatic Diseases

Abstract

The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of disorders characterized by symmetric proximal muscle weakness and elevated serum levels of enzymes derived from skeletal muscle. These include creatine phosphokinase (CPK), aldolase, aspartate, and alanine aminotransferases (AST and ALT), and lactate dehydrogenase (LDH). In addition, electromyography (EMG), magnetic resonance imaging (MRI), and muscle histology show changes indicative of nonsupparative inflammation (Table 18A-1) (1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344–347, 403–407.

    Article  CAS  PubMed  Google Scholar 

  2. Lindsley CB. Juvenile dermatomyositis update. Curr Opin Rheumatol 2006;8:174–177.

    Google Scholar 

  3. Targoff IN. Myositis specific autoantibodies. Curr Opin Rheumatol 2006;8:196–206.

    CAS  Google Scholar 

  4. Santmyire-Rosenberger B, Dugan EM. Skin involvement in dermatomyositis. Curr Opin Rheumatol 2003;15:714–722.

    Article  PubMed  Google Scholar 

  5. Kang EH, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology 2005;44:1282–1286.

    Article  CAS  PubMed  Google Scholar 

  6. Schnabel A, Hellmich B, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis. Curr Rheum Rep 2005;7:99–105.

    Article  CAS  Google Scholar 

  7. Bonnefoy O, et al. Serial chest CT findings in interstitial lung disease associated with polymyositis-dermatomyositis. Eur J Radiol 2004;49:235–244.

    Article  PubMed  Google Scholar 

  8. Yazici Y, Kagen LJ. Cardiac involvement in myositis. Curr Opin Rheumatol 2002;14:663–665.

    Article  PubMed  Google Scholar 

  9. Buchbinder R, Hill CL. Malignancy in patients with inflammatory myopathy. Curr Rheum Rep 2002;4:415–426.

    Article  Google Scholar 

  10. Whitmore SE, et al. Dermatomyositis sine myositis: association with malignancy. J Rheumatol 1996;23:101–105.

    CAS  PubMed  Google Scholar 

  11. Chen Y-J, Wu C-Y, Shen J-L. Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 2001;144:825–831.

    Article  CAS  PubMed  Google Scholar 

  12. Sultan SM. Clinical assessment in adult onset idiopathic inflammatory myopathy. Curr Opin Rheumatol 2004;16:668–672.

    Article  CAS  PubMed  Google Scholar 

  13. Targoff I. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2002;28:859–890.

    Article  PubMed  Google Scholar 

  14. Grundtman C, Lundberg IE. Pathogenesis of idiopathic inflammatory myopathies. Curr Opin Rheumatol 2006;8:188–195.

    CAS  Google Scholar 

  15. Scott DL, Kingsley GH. Use of imaging to assess patients with muscle disease. Curr Opin Rheumatol 2004;16:678–683.

    Article  PubMed  Google Scholar 

  16. Arakawa H, et al. Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation. Chest 2003;123:1096–1103.

    Article  PubMed  Google Scholar 

  17. Tansey D, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004;44:585–596.

    Article  CAS  PubMed  Google Scholar 

  18. Marton K, et al. Evaluation of oral manifestations and masticatory force in patients with polymyositis and dermatomyositis. J Oral Pathol Med 2005;34:164–169.

    Article  PubMed  Google Scholar 

  19. Ponyi A, et al. Disease course, frequency of relapses and survival of 73 patients with juvenile or adult dermatomyositis. Clin Exp Rheum 2005;23:50–56.

    CAS  Google Scholar 

  20. Ponyi A, et al. Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology 2005;44:83–88.

    Article  CAS  PubMed  Google Scholar 

  21. Dalakas MC. Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin North Am 2002;28:779–798, vi.

    Article  PubMed  Google Scholar 

  22. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I. Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984;16:193–208.

    Article  CAS  PubMed  Google Scholar 

  23. Crowe WE, Bove KE, Levinson JE, Hilton PK. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum 1982;25:126–139.

    Article  CAS  PubMed  Google Scholar 

  24. Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984;16:209–215.

    Article  CAS  PubMed  Google Scholar 

  25. Engel AG, Arahata K. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 1986;17:704–721.

    Article  CAS  PubMed  Google Scholar 

  26. Kissel JT, Mendell JR, Rammohan KW. Microvasculature deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986;314:329–334.

    Article  CAS  PubMed  Google Scholar 

  27. Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990;27:343–356.

    Article  CAS  PubMed  Google Scholar 

  28. Estruch R, Grau JM, Fernandez-Sola J, Casademont J, Monforte R, Urbano-Marquez A. Microvascular changes in skeletal muscle in idiopathic inflammatory myopathy. Hum Pathol 1992;23:888–895.

    Article  CAS  PubMed  Google Scholar 

  29. Figarella-Branger D, Civatte M, Bartoli C, Pellissier JF. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve 2003;28:659–682.

    Article  CAS  PubMed  Google Scholar 

  30. Goebels N, Michaelis D, Engelhardt M, et al. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 1996;97:2905–2910.

    Article  CAS  PubMed  Google Scholar 

  31. O’Hanlon TP, Carrick DM, Arnett FC, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in Caucasians. Medicine (Baltimore) 2005;84:338–349.

    Article  Google Scholar 

  32. Reed AM, Ytterberg SR. Genetic and environmental risk factors for idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2002;28:891–916.

    Article  PubMed  Google Scholar 

  33. O’Hanlon TP, Carrick DM, Targoff IN, et al. HLA-A, -B, -DRB1 and -DQA1 allelic profiles for the idiopathic inflammatory myopathies: distinct immunogenetic risk and protective factors distinguish European American patients with different myositis autoantibodies. Medicine 2006;85:111–127.

    Article  PubMed  Google Scholar 

  34. Lyon MG, Bloch DA, Hollak B, Fries JF. Predisposing factors in polymyositis-dermatomyositis: results of a nationwide survey. J Rheumatol 1989;16:1218–1224.

    CAS  PubMed  Google Scholar 

  35. Dalakas MC. Mechanisms of disease. Signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol 2006;2:219–227.

    Article  CAS  PubMed  Google Scholar 

  36. Nagaraju K, Rider LG, Fan C, et al. Endothelial cell activation and neovascularization are prominent in dermatomyositis. J Autoimmune Dis 2006;3:2.

    Article  PubMed  Google Scholar 

  37. Fall N, Bove KE, Stringer K, et al. Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy. Arthritis Rheum 2005;52:3175–3180.

    Article  CAS  PubMed  Google Scholar 

  38. Tezak Z, Hoffman EP, Lutz JL, et al. Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002;168:4154–4163.

    CAS  PubMed  Google Scholar 

  39. Greenberg SA, Sanoudou D, Haslett JN, et al. Molecular profiles of inflammatory myopathies. Neurology 2002;59:1170–1182.

    CAS  PubMed  Google Scholar 

  40. Raju R, Dalakas MC. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIG and biological validation of clinically relevant genes. Brain 2005;128:1887–1896.

    Article  PubMed  Google Scholar 

  41. Nagaraju K, Raben N, Loeffler L, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A 2000;97:9209–9214.

    Article  CAS  PubMed  Google Scholar 

  42. Nagaraju K, Casciola-Rosen L, Lundberg I, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005;52:1824–1835.

    Article  CAS  PubMed  Google Scholar 

  43. Nogalska A, Engel WK, McFerrin J, Kokame K, Komano H, Askanas V. Homocysteine-induced endoplasmic reticulum protein (Herp) is up-regulated in sporadic inclusion-body myositis and in endoplasmic reticulum stress-induced cultured human muscle fibers. J Neurochem 2006;96:1491–1499.

    Article  CAS  PubMed  Google Scholar 

  44. Miller FW, Rider LG, Chung YL, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 2001;40:1262–1273.

    Article  CAS  PubMed  Google Scholar 

  45. Rider LG, Giannini EH, Brunner HI, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004;50:2281–2290.

    Article  PubMed  Google Scholar 

  46. Oddis CV, Rider LG, Reed AM, et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005;52:2607–2615.

    Article  PubMed  Google Scholar 

  47. Guzman J, Petty RE, Malleson PN. Monitoring disease activity in juvenile dermatomyositis: the role of von Willebrand factor and muscle enzymes. J. Rheumatol 1994;21:739–743.

    CAS  PubMed  Google Scholar 

  48. Johnston JD, Lloyd M, Mathews JA, et al. Racial variation in serum creatine kinase levels. J Roy Soc Med 1996;89:462–464.

    CAS  PubMed  Google Scholar 

  49. Scott DL, Kingsley GH. Use of imaging to assess patients with muscle disease. Curr Opin Rheumatol 2004;16:678–683.

    Article  PubMed  Google Scholar 

  50. Dion E, Cherin P, Payan C, et al. Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. J Rheumatol 2002;29:1897–1906.

    PubMed  Google Scholar 

  51. Schnabel A, Hellmich B, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis. Curr Rheum Rep 2005;7:99–105.

    Article  CAS  Google Scholar 

  52. Targoff IN. Idiopathic inflammatory myopathy: autoantibody update. Curr Rheum Rep 2002;4:434–441.

    Article  Google Scholar 

  53. Brouwer R, Hengstman GJ, Egberts WT, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60:116–123.

    Article  CAS  PubMed  Google Scholar 

  54. Kao AH, Lacomis DH, Lucas M, et al. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004;50:209–215.

    Article  CAS  PubMed  Google Scholar 

  55. Hengstman GJ, Brouwer R, Egberts WT, et al. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis-specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 2002;249:69–75.

    Article  CAS  PubMed  Google Scholar 

  56. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96–100.

    Article  CAS  PubMed  Google Scholar 

  57. Baer AN. Advances in the therapy of idiopathic inflammatory myopathies. Curr Opin Rheumatol 2006;18:236–241.

    Article  CAS  PubMed  Google Scholar 

  58. Villalba L, Hick JE, Adams EM, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998;41:392–399.

    Article  CAS  PubMed  Google Scholar 

  59. Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005;52:2439–2446.

    Article  CAS  PubMed  Google Scholar 

  60. Barohn RJ, Amato AA, Sahenk Z, et al. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 1995;45:1302–1304.

    CAS  PubMed  Google Scholar 

  61. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993–2000.

    Article  CAS  PubMed  Google Scholar 

  62. Levine TD. Rituximab in the treatment of dermatomy-ositis: an open-label pilot study. Arthritis Rheum 2005;52:601–607.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, The University of Oklahoma College of Medicine, Tulsa, OK, USA

    Robert L. Wortmann MD, FACP, FACR (Professor and C. S. Lewis, Jr., MD Chair of Medicine)

Authors
  1. Robert L. Wortmann MD, FACP, FACR
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Arthritis Foundation, Atlanta, GA, USA

    John H. Klippel MD (President and CEO) (President and CEO)

  2. Massachusetts General Hospital, Boston, MA, USA

    John H. Stone MD, MPH (Associate Physician, Deputy Editor for Rheumatology) (Associate Physician, Deputy Editor for Rheumatology)

  3. Division of Rheumatology & Women’s Health, University of Kentucky, Lexington, KY, USA

    Leslie J. Crofford MD (Gloria W. Singletary Professor of Internal Medicine, Chief) (Gloria W. Singletary Professor of Internal Medicine, Chief)

  4. Arthritis Foundation, Atlanta, GA, USA

    Patience H. White MD, MA (Chief Public Health Officer) (Chief Public Health Officer)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Wortmann, R.L. (2008). Idiopathic Inflammatory Myopathies. In: Klippel, J.H., Stone, J.H., Crofford, L.J., White, P.H. (eds) Primer on the Rheumatic Diseases. Springer, New York, NY. https://doi.org/10.1007/978-0-387-68566-3_18

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-68566-3_18

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-35664-8

  • Online ISBN: 978-0-387-68566-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation